|
US2020370016A1
|
|
Methods of generating enucleated erythroid cells
|
|
US2020338129A1
|
|
Compositions including enucleated erythroid cells
|
|
US2020291355A1
|
|
Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
|
|
US2020172597A1
|
|
Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use
|
|
WO2019183292A1
|
|
Therapeutic cell systems and methods for treating hyperuricemia and gout
|
|
US2019309271A1
|
|
Therapeutic cell systems and methods for treating homocystinuria
|
|
KR20200140279A
|
|
Therapeutic cell systems and methods for treating cancer and infectious diseases
|
|
WO2019140116A2
|
|
Amplifiable rnas for therapeutic cell systems
|
|
WO2019133881A1
|
|
Gene editing and targeted transcriptional modulation for enginerering erythroid cells
|
|
EP3727434A1
|
|
Artificial antigen presenting cells and methods of use
|
|
WO2019090148A2
|
|
Compositions and methods related to therapeutic cell systems for tumor growth inhibition
|
|
EP3672602A1
|
|
Lipid nanoparticle methods and compositions for producing engineered erythroid cells
|
|
CN110520522A
|
|
Functionalization erythroid cells
|
|
WO2018102740A1
|
|
Compositions and methods related to cell systems for penetrating solid tumors
|
|
US2020172867A1
|
|
Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
|
|
WO2019017940A1
|
|
Compositions and methods related to multimodal therapeutic cell systems for infectious disease
|
|
WO2018009838A1
|
|
Compositions and methods related to therapeutic cell systems expressing exogenous rna
|
|
CA3010510A1
|
|
Compositions and methods related to multimodal therapeutic cell systems for immune indications
|
|
WO2016183482A1
|
|
Membrane-receiver complex therapeutics
|
|
CN106456744A
|
|
Methods and compositions for immunomodulation
|
